Literature DB >> 29450850

Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature.

Yanxia Chen1, Xingqi Huang2, Sujie Zheng3, Zhongliang Zhu3, Wei Yang3, Jinlin Liu4,5.   

Abstract

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is characterized by recurrent episodes of inflammation with fever, abdominal pain, chest pain, rash, myalgia, arthralgia, conjunctivitis, and periorbital edema. This condition is a rare autosomal dominant disease that is strongly associated with heterozygous mutations in the tumor necrosis factor (TNF) receptor super family 1A (TNFRSF1A) gene. This condition is believed to be more common in Western countries than in Asian countries, and the AA amyloidosis rate for European countries is estimated to be 10%. Herein, we report the case of a 14-year-old girl with recurrent fever and arthralgia with inflammatory marker elevation for 10 years. After extensive investigation of the infectious etiology with negative results and similar phenomenon observed within her family, the diagnosis of TRAPS was made based on next-generation sequencing, which revealed a T50M mutation; she was also sensitive to corticosteroids. Although none of our TRAPS patients developed AA amyloidosis, we suggest the continual monitoring of urinalysis results and serum amyloid A concentrations during long-term follow-up. Moreover, we also reviewed the related literature and found no Asian patients who had developed AA amyloidosis.

Entities:  

Keywords:  Arthralgia; Chinese patients; Recurrent fever; TRAPS

Mesh:

Year:  2018        PMID: 29450850     DOI: 10.1007/s10067-018-4023-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

Authors:  M F McDermott; I Aksentijevich; J Galon; E M McDermott; B W Ogunkolade; M Centola; E Mansfield; M Gadina; L Karenko; T Pettersson; J McCarthy; D M Frucht; M Aringer; Y Torosyan; A M Teppo; M Wilson; H M Karaarslan; Y Wan; I Todd; G Wood; R Schlimgen; T R Kumarajeewa; S M Cooper; J P Vella; C I Amos; J Mulley; K A Quane; M G Molloy; A Ranki; R J Powell; G A Hitman; J J O'Shea; D L Kastner
Journal:  Cell       Date:  1999-04-02       Impact factor: 41.582

Review 2.  Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

Authors:  Francesco La Torre; Maurizio Muratore; Antonio Vitale; Fulvio Moramarco; Laura Quarta; Luca Cantarini
Journal:  Rheumatol Int       Date:  2015-06-06       Impact factor: 2.631

3.  Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers.

Authors:  Silvia Federici; Maria Pia Sormani; Seza Ozen; Helen J Lachmann; Gayane Amaryan; Patricia Woo; Isabelle Koné-Paut; Natacha Dewarrat; Luca Cantarini; Antonella Insalaco; Yosef Uziel; Donato Rigante; Pierre Quartier; Erkan Demirkaya; Troels Herlin; Antonella Meini; Giovanna Fabio; Tilmann Kallinich; Silvana Martino; Aviel Yonatan Butbul; Alma Olivieri; Jasmin Kuemmerle-Deschner; Benedicte Neven; Anna Simon; Huri Ozdogan; Isabelle Touitou; Joost Frenkel; Michael Hofer; Alberto Martini; Nicolino Ruperto; Marco Gattorno
Journal:  Ann Rheum Dis       Date:  2015-01-30       Impact factor: 19.103

4.  Familial Mediterranean Fever in Armenians. Analysis of 100 cases.

Authors:  A D Schwabe; R S Peters
Journal:  Medicine (Baltimore)       Date:  1974-11       Impact factor: 1.889

5.  Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.

Authors:  Prashantha M Vaitla; Paul M Radford; Patrick J Tighe; Richard J Powell; Elizabeth M McDermott; Ian Todd; Elizabeth Drewe
Journal:  Arthritis Rheum       Date:  2011-04

Review 6.  From bench to bedside and back again: translational research in autoinflammation.

Authors:  Dirk Holzinger; Christoph Kessel; Alessia Omenetti; Marco Gattorno
Journal:  Nat Rev Rheumatol       Date:  2015-06-16       Impact factor: 20.543

Review 7.  The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation.

Authors:  Kalpana Manthiram; Qing Zhou; Ivona Aksentijevich; Daniel L Kastner
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

Review 8.  Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in Japan: a review of the literature.

Authors:  Masakazu Washio; Teruaki Nakano; Yasushi Kawaguchi; Kae Takagi; Chikako Kiyohara; Hiroshi Tsukamoto; Shoji Tokunaga; Takahiko Horiuchi
Journal:  Mod Rheumatol       Date:  2012-08-24       Impact factor: 3.023

9.  Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics.

Authors:  Elke Lainka; Ulrich Neudorf; Peter Lohse; Christian Timmann; Silvia Stojanov; Kristina Huss; Rudiger von Kries; Tim Niehues
Journal:  Rheumatology (Oxford)       Date:  2009-06-18       Impact factor: 7.580

10.  The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry.

Authors:  H J Lachmann; R Papa; K Gerhold; L Obici; I Touitou; L Cantarini; J Frenkel; J Anton; I Kone-Paut; M Cattalini; B Bader-Meunier; A Insalaco; V Hentgen; R Merino; C Modesto; N Toplak; R Berendes; S Ozen; R Cimaz; A Jansson; P A Brogan; P N Hawkins; N Ruperto; A Martini; P Woo; M Gattorno
Journal:  Ann Rheum Dis       Date:  2013-08-21       Impact factor: 19.103

View more
  1 in total

1.  LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b.

Authors:  Fan Zhang; Bai-Hua Luo; Qi-Hui Wu; Qing-Ling Li; Ke-Da Yang
Journal:  Mol Med       Date:  2022-01-04       Impact factor: 6.354

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.